These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26875064)

  • 41. Preventing osteoporosis-related fractures: an overview.
    Gass M; Dawson-Hughes B
    Am J Med; 2006 Apr; 119(4 Suppl 1):S3-S11. PubMed ID: 16563939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population].
    Azagra R; Roca G; Martín-Sánchez JC; Casado E; Encabo G; Zwart M; Aguyé A; Díez-Pérez A;
    Med Clin (Barc); 2015 Jan; 144(1):1-8. PubMed ID: 24461732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis.
    O'Connell MB
    J Manag Care Pharm; 2006 Jul; 12(6 Suppl A):S10-9; quiz S26-8. PubMed ID: 17269853
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
    Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures.
    Phillips HK; Harrison SJ; Akrawi H; Sidhom SA
    Injury; 2017 Jun; 48(6):1159-1164. PubMed ID: 28410753
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
    Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
    Wien Med Wochenschr Suppl; 2009; (122):1-34. PubMed ID: 19484202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Guidelines for the diagnosis, prevention and treatment of osteoporosis. Italian Osteoporosis, Mineral Metabolism, and Skeletal Diseases Society].
    Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro
    Minerva Endocrinol; 2013 Mar; 38(1 Suppl 1):1-30. PubMed ID: 23539106
    [No Abstract]   [Full Text] [Related]  

  • 50. Osteoporosis Management.
    Batur P; Rice S; Barrios P; Sikon A
    J Womens Health (Larchmt); 2017 Aug; 26(8):918-921. PubMed ID: 28686517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis.
    Eudy-Byrne RJ; Gillespie W; Riggs MM; Gastonguay MR
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):599-609. PubMed ID: 29081020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment holidays in patients with postmenopausal osteoporosis: whom and when?
    Reyes García R; García Martín A; Muñoz-Torres M
    Endocrinol Nutr; 2012 Dec; 59(10):573-4. PubMed ID: 23031434
    [No Abstract]   [Full Text] [Related]  

  • 53. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
    J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Update on osteoporosis treatment.
    Nogués X; Martinez-Laguna D
    Med Clin (Barc); 2018 Jun; 150(12):479-486. PubMed ID: 29179892
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treating with what? Therapy for how long?].
    MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
    [No Abstract]   [Full Text] [Related]  

  • 56. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
    N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Osteoporosis prevention and management: an evidence-based review.
    Kleerekoper M; Gold DT
    Clin Obstet Gynecol; 2008 Sep; 51(3):556-63. PubMed ID: 18677150
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of daily teriparatide treatment for osteoporosis in men.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.